Cannabioids as a New Intervention for Amphetamine Dependence

Amphetamine Addiction Clinical Trial

Official title:

Cannabinoids as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02952196
• Other study ID #: 16.181
• Status: Withdrawn
• Phase: Phase 2
• Start date: November 2016
• Est. completion date: December 2017

Study information

• Verified date: January 2019
• Source: Centre hospitalier de l'Université de Montréal (CHUM)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Current DSM-V criteria for amphetamine use disorder
• Ability to give valid, informed consent

Exclusion Criteria:

• Severe and/or unstable hepatic, neurologic (including diagnosis of seizures), cardiac (including arrhythmias) or renal disease, or any other severe or unstable medical condition that precludes safe participation in the study according to the study physician.
• Severe psychiatric condition (history of schizophrenia, schizoaffective disorder or bipolar disorder; current acute psychosis, mania or severe suicidality
• Any serious medical condition or psychiatric illness that precludes the subject from signing the informed consent form

Related Conditions & MeSH terms

• Amphetamine Addiction
• Amphetamine-Related Disorders

Intervention

Drug:
• drug administration
administering drug to patient with amphetamine addiction

Locations

Country	Name	City	State
Canada	Centre hospitalier de l'Université de Montréal	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Centre hospitalier de l'Université de Montréal (CHUM)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	assessing amphetamine craving	using questionnaire to assess craving and taking vital signs	everyday during the study (that will last 3 days for each participants)